Connection

BIYKEM BOZKURT to Hypoglycemic Agents

This is a "connection" page, showing publications BIYKEM BOZKURT has written about Hypoglycemic Agents.
Connection Strength

0.354
  1. Baseline characteristics in the SYNCHRONIZE?-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026 Feb; 28(2):1490-1498.
    View in: PubMed
    Score: 0.175
  2. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011 Jan; 4(1):53-8.
    View in: PubMed
    Score: 0.062
  3. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol. 2007 Jul 03; 50(1):32-6.
    View in: PubMed
    Score: 0.049
  4. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes Obes Metab. 2022 11; 24(11):2071-2080.
    View in: PubMed
    Score: 0.035
  5. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.